Wissenschaftliche Publikationen | Max Delbrück Center

190 Ergebnisse:

Active Filter:

Blankenstein, Thomas Prof. Dr.

05. März 2026 / bioRxiv

Oncogene inactivation-induced senescence facilitates tumor relapse

P. Schmitt
K. Hönig
M.T. Norcia
M.F. Nogueira
V. Flore
I.S. Vesperinas
M. Villoro-Agud
L. Peng
Z. Safyürek
M. Tariq
A. Milojkovic
K. Anders
E. Schröck
S. Sauer
B. Uyar
A. Akalin
G. Willimsky
S. Haas
I. Martínez-Reyes
T. Blankenstein

05. März 2026 / Blood

A CD22-specific T-cell receptor enables effective adoptive T-cell therapy for B-cell malignancies

Simone Rhein
Neşe Çakmak-Görür
Corinna Grunert
Sarah Hayder Jalal Al-Tabatabaee
Nazli Serin
Matthias Leisegang
Stefanos Timiliotis
Luisa Sophie Ohlmeier
Cäcilia Freund
Gerald Willimsky
Frank Konietschke
Elisa Kieback
Sarah K. Tasian
Bjoern Chapuy
Ulrich Keller
Thomas Blankenstein
Antonio Pezzutto
Antonia Busse

01. Januar 2026 / Human Gene Therapy

In remembrance of Professor Zelig Eshhar: a life committed to CAR-T

Reno Debets
Robert Hawkins
David Gilham
Guy Gorochov
Ton Schumacher
Wolfgang Uckert
Thomas Blankenstein
Dorothy Crawford
Naomi Taylor
János Szöllösi
Hans Stauss
Anna Mondino
Paola Allavena
Balbino Alarcón
Hildegard Büning
Hinrich Abken

01. Juli 2025 / Nature Communications

Mice with a diverse human T cell receptor repertoire selected on multiple HLA class I molecules

A. Dhamodaran
X. Chen
N. Fellmer
D. Agrawal
E. Danner
R. Kühn
T. Blankenstein

Juni 2025 / Journal for ImmunoTherapy of Cancer

Enhanced mutanome analysis towards the induction of neoepitope-reactive T-cell responses for personalized immunotherapy of pancreatic cancer

M. Volkmar
D. Hoser
C. Lauenstein
J. Rebmann
A. Hotz-Wagenblatt
J. Rieger
I. Poschke
J.P. Becker
A.B. Riemer
M. Sprick
A. Trumpp
O. Strobel
T. Blankenstein
G. Willimsky
R. Offringa

23. Mai 2025 / Science Advances

CD8(+) T cell-derived CD40L mediates noncanonical cytotoxicity in CD40-expressing cancer cells

P. Schiele
A. Sada Japp
R. Stark
J.J. Sattelberg
C. Nikolaou
G. Kornhuber
P. Abbasi
N. Ding
S. Rosnev
S. Meinke
K. Mühle
L. Loyal
J. Braun
M. Dingeldey
S. Durlanik
N. Matzmohr
D. Ponikwicka-Tyszko
S. Wolczynski
N.A. Rahman
I. Taniuchi
S. Schlickeiser
C. Giesecke-Thiel
T. Blankenstein
I.K. Na
A. Thiel
M. Frentsch

02. Mai 2025 / Journal for ImmunoTherapy of Cancer

Selection of therapeutically effective T-cell receptors from the diverse tumor-bearing repertoire

L. Rosenberger
L. Hansmann
V. Anastasopoulou
S.P. Wolf
K. Drousch
C. Moewes
X. Feng
G. Cao
J. Huang
P.Y. Yew
E. Strønen
T. Kato
N. Saligrama
J. Olweus
Y. Nakamura
G. Willimsky
T. Blankenstein
H. Schreiber
M. Leisegang

Februar 2025 / Pharmacological Research

Targeting MYCN upregulates L1CAM tumor antigen in MYCN-dysregulated neuroblastoma to increase CAR T cell efficacy

L. Grunewald
L. Andersch
K. Helmsauer
S. Schwiebert
A. Klaus
A.G. Henssen
T. Straka
M. Lodrini
S.G. Wicha
S. Fuchs
F. Hertwig
F. Westermann
A. Vitali
C. Caramel
G. Büchel
M. Eilers
K. Astrahantseff
A. Eggert
U.E. Höpken
J.H. Schulte
T. Blankenstein
K. Anders
A. Künkele

27. Januar 2025 / Frontiers in Immunology

T cell receptors specific for an imatinib-induced mutation in BCR-ABL for adoptive T cell therapy

M.T. Hsu
G. Willimsky
L. Hansmann
T. Blankenstein

Januar 2025 / Haematologica

A phase I study of MAGE-A1-targeted T1367 T-cell receptor-based cell therapy in patients with advanced multiple myeloma

J. Krüger
M. Obenaus
I.W. Blau
D. Hoser
M. Vaegler
H. Rauschenbach
I. Anagnostopoulos
K. Jöhrens
V. Scheuplein
E. Kieback
J. Böhme
A.C. Von Brünneck
J. Krönke
A. Busse
G. Willimsky
T. Blankenstein
A. Pezzutto
U. Keller
A. Nogai